Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 421 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR How Your Oncology Nurse Can Help You During Cancer February 22, 2023 CancerLand Bookshelf : Loosen July 26, 2021 High Frequency of Germline ATM Variants in CLL November 11, 2022 Breast-Cancer Mom Is Living On 84 Pence As She Fights For... April 15, 2019 Load more HOT NEWS For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Immunotherapy treatment fast tracked to treat lung cancer patients in England Rookie Cop Saves Infant From Choking EMA Recommends Extension of Indications for Talazoparib
